Effects of sitagliptin on blood pressure and heart rate in response to intraduodenal glucose infusion in patients with Type 2 diabetes: A potential role for glucose-dependent insulinotropic polypeptide?

Diabetic Medicine

Volumn 32, Issue 5, 2015, Pages 595-600

  Wu, T ^a,b   Trahair, L G ^a,b   Bound, M J ^a,b   Deacon, C F ^c   Horowitz, M ^a,b   Rayner, C K ^a,b   Jones, K L ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PLACEBO; SITAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INFUSION; HEART RATE; HUMAN; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; BLOOD PRESSURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; DUODENUM; HOMEOSTASIS; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR;

ADMINISTRATION, ORAL; AGED; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DUODENUM; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; HEART RATE; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; RETROSPECTIVE STUDIES; SITAGLIPTIN PHOSPHATE; TIME FACTORS;

EID: 84928040555     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12622     Document Type: Article

References (20)

1. Gentilcore D, Jones KL, O'Donovan DG, Horowitz M. Postprandial hypotension - novel insights into pathophysiology and therapeutic implications. Curr Vasc Pharmacol 2006; 4: 161-171.
2. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33: 187-215.
3. Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol 2013; 10: 73-84.
4. Brener W, Hendrix TR, McHugh PR. Regulation of the gastric emptying of glucose. Gastroenterology 1983; 85: 76-82.
5. Trahair LG, Vanis L, Gentilcore D, Lange K, Rayner CK, Horowitz M et al. Effects of variations in duodenal glucose load on blood pressure, heart rate, superior mesenteric artery blood flow and plasma noradrenaline in healthy young and older subjects. Clin Sci (Lond) 2012; 122: 271-279.
6. Trahair LG, Horowitz M, Rayner CK, Gentilcore D, Lange K, Wishart JM et al. Comparative effects of variations in duodenal glucose load on glycemic, insulinemic, and incretin responses in healthy young and older subjects. J Clin Endocrinol Metab 2012; 97: 844-851.
7. Ma J, Pilichiewicz AN, Feinle-Bisset C, Wishart JM, Jones KL, Horowitz M et al. Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes. Diabet Med 2012; 29: 604-608.
8. Wu T, Ma J, Bound MJ, Checklin H, Deacon CF, Jones KL et al. Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans, and patients with type 2 diabetes treated with or without metformin. Diabetes 2014; 63: 2776-2287.
9. Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. Br Med J (Clin Res Ed) 1982; 285: 916-918.
10. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003; 88: 2706-2713.
11. Lindgren O, Carr RD, Deacon CF, Holst JJ, Pacini G, Mari A et al. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab 2011; 96: 2519-2524.
12. Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: Part 1-Correlation within subjects. BMJ 1995; 310: 446.
13. Amland PF, Jorde R, Aanderud S, Burhol PG, Giercksky KE. Effects of intravenously infused porcine GIP on serum insulin, plasma C-peptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state. Scand J Gastroenterol 1985; 20: 315-320.
14. Svensson AM, Efendic S, Ostenson CG, Jansson L. Gastric inhibitory polypeptide and splanchnic blood perfusion: augmentation of the islet blood flow increase in hyperglycemic rats. Peptides 1997; 18: 1055-1059.
15. Fara JW, Salazar AM. Gastric inhibitory polypeptide increases mesenteric blood flow. Proc Soc Exp Biol Med 1978; 158: 446-448.
16. Wice BM, Reeds DN, Tran HD, Crimmins DL, Patterson BW, Dunai J et al. Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes. Diabetes 2012; 61: 1793-1800.
17. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981; 30: 219-225.
18. Young CN, Deo SH, Chaudhary K, Thyfault JP, Fadel PJ. Insulin enhances the gain of arterial baroreflex control of muscle sympathetic nerve activity in humans. J Physiol 2010; 588: 3593-3603.
19. Pedersen-Bjergaard U, Host U, Kelbaek H, Schifter S, Rehfeld JF, Faber J et al. Influence of meal composition on postprandial peripheral plasma concentrations of vasoactive peptides in man. Scand J Clin Lab Invest 1996; 56: 497-503.
20. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447-1456.